Regorafenib-associated adverse event management in colorectal and gastrointestinal stromal cancer patients: A systematic review and meta-analysis.

Ganfeng Xie,Yuzhu Gong,Shuang Wu,Chong Li,Songtao Yu,Zhe Wang,Jianfang Chen,Quanfeng Zhao,Jianjun Li,Houjie Liang

Regorafenib-associated adverse event management in colorectal and gastrointestinal stromal cancer patients: A systematic review and meta-analysis.

2019

Ganfeng Xie
Yuzhu Gong
Shuang Wu
Chong Li
Songtao Yu
Zhe Wang
Jianfang Chen
Quanfeng Zhao
Jianjun Li
Houjie Liang

e15181Background: Adverse events (AEs) observed in regorafenib treated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST) often require treatment modification. However, ...

Keywords:

Meta-analysis
Cancer
Regorafenib
Oncology
Stromal cell
Pathology
Internal medicine
Adverse effect
Medicine
GiST
Colorectal cancer
Treatment modification

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations